X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AP303 is a pan-inhibitor of sodium-dependent phosphate transporters. It is being evaluated for the treatment of autosomal dominant polycystic kidney disease.
Lead Product(s): AP303
Therapeutic Area: Genetic Disease Product Name: AP303
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2024
Details:
AP306 (EOS789) is an oral inhibitor of phosphate transporters, NaPi-IIb, PiT-1, PiT-2. It is being evaluated in phase 2 clinical trials for the treatment of patients with hyperphosphatemia on hemodialysis.
Lead Product(s): EOS789
Therapeutic Area: Nephrology Product Name: AP-306
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
Proceeds raised will help accelerate the development of AP-302 and Alebund’s other clinical programs, the construction of the manufacturing site, the research of pre-clinical assets, and the expansion of Company’s talent pool.
Lead Product(s): AP-302
Therapeutic Area: Immunology Product Name: AP-302
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: 3H Health Investment
Deal Size: $54.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 14, 2021
Details:
Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.
Lead Product(s): Solnatide
Therapeutic Area: Nephrology Product Name: AP-301
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Quan Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
